NEPH · Nephros Inc · Insider Trading

Represents a sale of certain shares of common stock from the Wexford Entities to Amron Holdings, the proceeds of which were distributed to certain underlying investors of the Wexford Entities. No Wexford Entities shall receive any compensation, directly or indirectly, in connection with the transaction described herein.

Represents the common stock of the Issuer held by Amron Holdings LLC ("Amron Holdings").

Arthur Amron may, by reason of his status as a controlling person of Amron Holdings, be deemed to own beneficially the securities held by Amron Holdings. Mr. Amron holds the power to vote and to dispose of the securities held by Amron Holdings.

Represents a sale of certain shares of common stock from the Distributing Entities to an entity controlled by Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital LP ("Wexford Capital"), the proceeds of which were distributed to certain underlying investors of the Distributing Entities. No Distributing Entities shall receive any compensation, directly or indirectly, in connection with the transaction described herein.

Represents the common stock of the Issuer held by WST.

Wexford Capital may, by reason of its status as (i) sub-advisor of WST, (ii) investment manager of WP11 and (iii) manager of WPIC2, (WPIC2, together with WST and WP11, the "Wexford Entities"), be deemed to own beneficially the shares of Common Stock held by the Wexford Entities. Wexford GP may, by reason of its status as General Partner of Wexford Capital, be deemed to own beneficially the shares of Common Stock held by the Wexford Entities. Each of Messrs. Davidson and Jacobs may, by reason of his status as a controlling person of Wexford GP and WP Advisors, be deemed to own beneficially the shares of Common Stock held by the Wexford Entities and WP Advisors.

Each of Wexford Capital, Wexford GP, Davidson and Jacobs shares the power to vote and to dispose of the shares of Common Stock held by the Wexford Entities. Each of Davidson and Jacobs shares the power to vote and to dispose of the shares of Common Stock held by WP Advisors. Each of Wexford Capital, Wexford GP and Messrs. Davidson and Jacobs disclaims beneficial ownership of the shares of Common Stock held by the Wexford Entities and/or WP Advisors, as applicable, and this report shall not be deemed as an admission that they are the beneficial owner of such securities except, in the case of Davidson and Jacobs, to the extent of their respective pecuniary interests therein.

Represents an in-kind distribution from Wexford Partners 11, L.P. ("WP11"), Wexford 11 Advisors LLC ("WP Advisors") and WPIC 2 LLC ("WPIC2", and together with WP11 and WP Advisors, the "Wexford Entities") that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration.

Represents an in-kind distribution from Wexford Partners 11, L.P. ("WP11"), Wexford 11 Advisors LLC ("WP Advisors") and WPIC 2 LLC ("WPIC2", and together with WP11 and WP Advisors, the "Wexford Entities") that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration.

Represents the common stock of the Issuer held by Amron Holdings LLC ("Amron Holdings").

Arthur Amron may, by reason of his status as a controlling person of Amron Holdings, be deemed to own beneficially the securities held by Amron Holdings. Mr. Amron holds the power to vote and to dispose of the securities held by Amron Holdings.

Represents an in-kind distribution of certain shares of common stock from Wexford Partners 11, L.P. ("WP11"), Wexford 11 Advisors LLC ("WP Advisors") and WPIC 2 LLC ("WPIC2", and together with WP11 and WP Advisors, the "Distributing Entities") that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration.

Represents the common stock of the Issuer held by the Distributing Entities and Wexford Spectrum Trading Limited ("WST").

Wexford Capital may, by reason of its status as (i) sub-advisor of WST, (ii) investment manager of WP11 and (iii) manager of WPIC2, (WPIC2, together with WST and WP11, the "Wexford Entities"), be deemed to own beneficially the shares of Common Stock held by the Wexford Entities. Wexford GP may, by reason of its status as General Partner of Wexford Capital, be deemed to own beneficially the shares of Common Stock held by the Wexford Entities. Each of Messrs. Davidson and Jacobs may, by reason of his status as a controlling person of Wexford GP and WP Advisors, be deemed to own beneficially the shares of Common Stock held by the Wexford Entities and WP Advisors.

Each of Wexford Capital, Wexford GP, Davidson and Jacobs shares the power to vote and to dispose of the shares of Common Stock held by the Wexford Entities. Each of Davidson and Jacobs shares the power to vote and to dispose of the shares of Common Stock held by WP Advisors. Each of Wexford Capital, Wexford GP and Messrs. Davidson and Jacobs disclaims beneficial ownership of the shares of Common Stock held by the Wexford Entities and/or WP Advisors, as applicable, and this report shall not be deemed as an admission that they are the beneficial owner of such securities except, in the case of Davidson and Jacobs, to the extent of their respective pecuniary interests therein.

Represents the net number of shares of common stock issued upon the cashless exercise of stock options to purchase 3,765 shares, after a portion of the option shares was withheld to satisfy the exercise price.

Includes shares of common stock granted to Wexford Capital LP ("Wexford Capital") as reported in Form 4s previously filed by Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital.

One-third of the options vested immediately upon the grant date of August 24, 2016. The remainder of the options vested in equal annual installments on each of the first and second anniversaries of the grant date.

Includes stock options granted to Wexford Capital as reported in Form 4s previously filed by Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital.

Shares issued to reporting person in lieu of cash fees for board service.

Shares issued to reporting person in lieu of cash fees for board service.

Options to purchase 30,631 shares vest on 11/1/2024 and options to purchase the remaining 91,893 shares vest quarterly in 12 equal amounts commencing on 2/1/2025.

Options to purchase 89,291 shares vest on 5/5/24 and options to purchase 267,874 shares vest quarterly in 12 equal amounts commencing on 8/5/24.

Shares issued to reporting person in lieu of cash fees for board service.

Options to purchase 1,000 shares vest on 3/16/2027 and options to purchase the remaining 3,000 shares vest quarterly in 12 equal amounts commencing on 6/16/2027.

This option vests as to 4,410 shares on each of 6/16/25 and 6/16/26 and 4,409 options vest on 6/16/27.

Options to purchase 13,589 shares vest on 3/27/2026 and options to purchase the remaining 40,770 shares vest quarterly in 12 equal amounts commencing on 6/27/2026.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents options granted to the reporting person for her service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2024. This option vests as to 2,350 shares on each of 1/1/25, 1/1/26 and 1/1/27.

Represents a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.237 to $2.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Represents a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.2138 to $2.2276, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.10 to $2.25, inclusive. The reporting person undertakes to provide Nephros Inc., any security holder of Nephros Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the set range set forth in this footnote.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Represents options granted to the reporting person for her service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Options to purchase 2,601 shares vest on 5/14/25 and options to purchase the remaining 7,805 shares vest quarterly in 12 equal amounts commencing on 8/14/25.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2023. This option vests as to 2,441 shares on each of 5/14/24, 5/14/25 and 5/14/26.

Represents an in-kind distribution by Wexford Capital LP ("Wexford Capital") to Arthur Amron that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration, in connection with his separation from service as an employee of Wexford Capital.

Represents an in-kind distribution by Wexford Capital LP ("Wexford Capital") to Arthur Amron that does not involve (i) a purchase or a sale of securities or (ii) any additional consideration, in connection with his separation from service as an employee of Wexford Capital.

Represents a weighted average price. These shares of common stock were purchased in multiple transactions at prices ranging from $2.3899 to $2.4857, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.

On December 13, 2023, the Company granted 9,291 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Amron in respect of his services as a member of the Board of Directors of the Company for 2023. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). At the request of Mr. Amron, the Restricted Stock was granted to Wexford Capital LP. The Restricted Stock vests 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2023. These shares of restricted stock vest 6 months following the grant date.

Options to purchase 30,631 shares vest on 11/1/24 and options to purchase the remaining 91,893 shares vest quarterly in 12 equal amounts commencing on 2/1/25.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.66 to $1.73, inclusive. The reporting person undertakes to provide Nephros Inc., any security holder of Nephros Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the set range set forth in this footnote.

Represents options granted to the reporting person for her service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for her service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.

Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.

Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.